Crohn's disease, budesonide, Budenofalk, IBD, ziekte van Crohn
Conditions
Interventions
None. This is a prospective, multicenter, observational study. This means that intervention is not the purpose of this study
patients will be treated solely as part of regular medical therapy. Therapeutic necessity will be the only determinant of selection of the medicine.
Sponsors
Dr. Falk Pharma Benelux B.V.
Eligibility
Inclusion criteria
Inclusion criteria: age > 18 years; seen in the outpatient department; have been prescribed Budenofalk granules or capsules for the treatment of mild to moderate active Crohn's disease; have received adequate information regarding this observational study and have voluntarily agreed to the use of their data
Exclusion criteria
Exclusion criteria: have severe active Crohn's disease; are being treated with corticosteroids for current flare; are hypersensitive to the active substance or any of the excipients; are enrolled and involved in an interventional study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The objective of this study is to obtain an insight into the treatment of acute Crohn’s disease with Budenofalk 9 mg granules and 3 mg capsules among outpatients attending regular gastroenterological practice. The primary outcome is the percentage of physicians who perform Budenofalk therapy as described in the SPC. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives include therapeutic adherence, treatment success, tolerability and safety, ease of use and pharmacy substitution. | — |
Contacts
Public ContactC. Koks
Dr. Falk Pharma Benelux B.V.
Outcome results
None listed